Kapetanovic IM, Torchin CD, Thompson CD, Miller TA, McNeilly PJ, Macdonald TL, et al. Potentially reactive cyclic carbamate metabolite of the antiepileptic drug felbamate produced by human liver tissue in vitro. Drug Metab Dispos 1998; 26 (11):1089–95.78 78 Popovic M, Nierkens S, Pieters R, Uetrecht J. Investigating the role of 2‐phenylpropenal in felbamate‐induced idiosyncratic drug reactions. Chem Res Toxicol 2004; 17 (12):1568–76.
79 79 Roller SG, Dieckhaus CM, Santos WL, Sofia RD, Macdonald TL. Interaction between human serum albumin and the felbamate metabolites 4‐Hydroxy‐5‐phenyl‐[1,3]oxazinan‐2‐one and 2‐phenylpropenal. Chem Res Toxicol 2002; 15(6):815–24.
80 80 Thompson CD, Kinter MT, Macdonald TL. Synthesis and in vitro reactivity of 3‐carbamoyl‐2‐phenylpropionaldehyde and 2‐phenylpropenal: putative reactive metabolites of felbamate. Chem Res Toxicol 1996; 9(8):1225–9.
81 81 Leone AM, Kao LM, McMillian MK, Nie AY, Parker JB, Kelley MF, et al. Evaluation of felbamate and other antiepileptic drug toxicity potential based on hepatic protein covalent binding and gene expression. Chem Res Toxicol 2007; 20(4):600–8.
82 82 Potschka H, Fedrowitz M, Loscher W. P‐Glycoprotein‐mediated efflux of phenobarbital, lamotrigine, and felbamate at the blood‐brain barrier: evidence from microdialysis experiments in rats. Neurosci Lett 2002; 327(3):173–6.
83 83 Potschka H, Fedrowitz M, Loscher W. Brain access and anticonvulsant efficacy of carbamazepine, lamotrigine, and felbamate in ABCC2/MRP2‐deficient TR‐ rats. Epilepsia 2003; 44 (12):1479–86.
84 84 Amery KV. Clinical evaluation of the effects of flucloxacillin in skin and soft tissue infections in the Ivory Coast. Pharmatherapeutica 1988; 5(3):193–7.
85 85 Harding JW, Knudsen ET. General practitioners' forum. Flucloxacillin in the treatment of skin and soft‐tissue infections. Practitioner 1970; 205 (230):801–6.
86 86 Lacey RW, Lewis EL. Further evolution of a strain of Staphylococcus aureus in vivo: evidence for significant inactivation of flucloxacillin by penicillinase. J Med Microbiol 1975; 8(2):337–47.
87 87 Brogi G. Experience in pediatrics with a combination of ampicillin and flucloxacillin drops. Minerva Pediatr 1979; 31 (10):813–8.
88 88 Chew R, Woods ML. Flucloxacillin does not achieve therapeutic cerebrospinal fluid levels against meticillin‐sensitive Staphylococcus aureus in adults: a case report and review of the literature. Int J Antimicrob Agents 2016; 47(3):229–31.
89 89 Ritchie SR, Rupali P, Roberts SA, Thomas MG. Flucloxacillin treatment of Staphylococcus aureus meningitis. Eur J Clin Microbiol Infect Dis 2007; 26(7):501–4.
90 90 Moghissi K, Lutley C, Green J, Moghissi AJ. A trial comparing the use of penicillin and streptomycin, and flucloxacillin and ampicillin prophylactically in patients undergoing major thoracic surgery. Br J Clin Pract 1981; 35 (7–8):250–3.
91 91 Wilson AP, Gruneberg RN, Treasure T, Sturridge MF. A clinical trial of teicoplanin compared with a combination of flucloxacillin and tobramycin as antibiotic prophylaxis for cardiac surgery: the use of a scoring method to assess the incidence of wound infection. J Hosp Infect. 1986; 7 Suppl A:105–12.
92 92 Holm S, Larsson SE. The penetration of flucloxacillin into cortical and cancellous bone during arthroplasty of the knee. Int Orthop 1982; 6(4):243–7.
93 93 Koek GH, Stricker BH, Blok AP, Schalm SW, Desmet VJ. Flucloxacillin‐associated hepatic injury. Liver 1994; 14(5):225–9.
94 94 Turner IB, Eckstein RP, Riley JW, Lunzer MR. Prolonged hepatic cholestasis after flucloxacillin therapy. Med J Aust 1989; 151 (11–12):701–5.
95 95 Teixeira M, Macedo S, Batista T, Martins S, Correia A, Matos LC. Flucloxacillin‐induced hepatotoxicity‐association with HLA‐B*5701. Rev Assoc Med Bras (1992). 2020; 66(1):12–7.
96 96 Nicoletti P, Aithal GP, Chamberlain TC, Coulthard S, Alshabeeb M, Grove JI, et al. Drug‐induced liver injury due to flucloxacillin: relevance of multiple human leukocyte antigen alleles. Clin Pharmacol Ther 2019; 106(1):245–53.
97 97 Daly AK, Donaldson PT, Bhatnagar P, Shen Y, Pe'er I, Floratos A, et al. HLA‐B*5701 genotype is a major determinant of drug‐induced liver injury due to flucloxacillin. Nat Genet 2009; 41(7):816–9.
98 98 Gath J, Charles B, Sampson J, Smithurst B. Pharmacokinetics and bioavailability of flucloxacillin in elderly hospitalized patients. J Clin Pharmacol 1995; 35(1):31–6.
99 99 Thijssen HH, Wolters J. The metabolic disposition of flucloxacillin in patients with impaired kidney function. Eur J Clin Pharmacol 1982; 22(5):429–34.
100 100 Dekker SJ, Dohmen F, Vermeulen NPE, Commandeur JNM. Characterization of kinetics of human cytochrome P450s involved in bioactivation of flucloxacillin: inhibition of CYP3A‐catalysed hydroxylation by sulfaphenazole. Br J Pharmacol. 2019; 176(3):466–77.
101 101 Lakehal F, Dansette PM, Becquemont L, Lasnier E, Delelo R, Balladur P, et al. Indirect cytotoxicity of flucloxacillin toward human biliary epithelium via metabolite formation in hepatocytes. Chem Res Toxicol 2001; 14(6):694–701.
102 102 Huwyler J, Wright MB, Gutmann H, Drewe J. Induction of cytochrome P450 3A4 and P‐glycoprotein by the isoxazolyl‐penicillin antibiotic flucloxacillin. Curr Drug Metab 2006; 7(2):119–26.
103 103 Jenkins RE, Meng X, Elliott VL, Kitteringham NR, Pirmohamed M, Park BK. Characterisation of flucloxacillin and 5‐hydroxymethyl flucloxacillin haptenated HSA in vitro and in vivo. Proteomics Clin Appl 2009; 3(6):720–9.
104 104 Waddington JC, Ali SE, Penman SL, Whitaker P, Hamlett J, Chadwick A, et al. Cell membrane transporters facilitate the accumulation of hepatocellular flucloxacillin protein adducts: implication in flucloxacillin‐induced liver injury. Chem Res Toxicol 2020, 33(12):2939–2943.
105 105 Cyr M, Brown CS. Nefazodone: its place among antidepressants. Ann Pharmacother 1996; 30(9):1006–12.
106 106 DeVane CL, Grothe DR, Smith SL. Pharmacology of antidepressants: focus on nefazodone. J Clin Psychiatry 2002; 63 Suppl 1:10–7.
107 107 Eison AS, Eison MS, Torrente JR, Wright RN, Yocca FD. Nefazodone: preclinical pharmacology of a new antidepressant. Psychopharmacol Bull 1990; 26(3):311–5.
108 108 Ellingrod VL, Perry PJ. Nefazodone: a new antidepressant. Am J Health Syst Pharm 1995; 52 (24):2799–812.
109 109 Goldberg RJ. Nefazodone: a novel antidepressant. Psychiatr Serv 1995; 46 (11):1113–4.
110 110 Aranda‐Michel J, Koehler A, Bejarano PA, Poulos JE, Luxon BA, Khan CM, et al. Nefazodone‐induced liver failure: report of three cases. Ann Intern Med 1999; 130 (4 Pt 1):285–8.
111 111 Conway CR, McGuire JM, Baram VY. Nefazodone‐induced liver failure. J Clin Psychopharmacol 2004; 24(3):353–4.
112 112 Eloubeidi MA, Gaede JT, Swaim MW. Reversible nefazodone‐induced liver failure. Dig Dis Sci 2000; 45(5):1036–8.
113 113 Lucena MI, Andrade RJ, Gomez‐Outes A, Rubio M, Cabello MR. Acute liver failure after treatment with nefazodone. Dig Dis Sci 1999; 44 (12):2577–9.
114 114 Schirren CA, Baretton G. Nefazodone‐induced acute liver failure. Am J Gastroenterol 2000; 95(6):1596–7.
115 115van Battum
